foxo4 dri human trials results The disordered p53 transactivation domain is the target of and the senolytic compound FOXO4-DRI FOXO4-DRI regulates endothelial cell senescence
Description
Structural design Design delivery systems with specific structures and morphologies, such as multilayer nanoparticles or core-shell structured microspheres, to achieve pulsed or targeted drug release
"Phenotypic differences in the effects of Selank on active avoidance conditioning." Neuroscience and Behavioral Physiology
Who is at Risk for Shingles
Today, I wanted to share an intriguing chapter in sleep research
